MX2010009782A - Tratamientos antitumorales mejorados. - Google Patents
Tratamientos antitumorales mejorados.Info
- Publication number
- MX2010009782A MX2010009782A MX2010009782A MX2010009782A MX2010009782A MX 2010009782 A MX2010009782 A MX 2010009782A MX 2010009782 A MX2010009782 A MX 2010009782A MX 2010009782 A MX2010009782 A MX 2010009782A MX 2010009782 A MX2010009782 A MX 2010009782A
- Authority
- MX
- Mexico
- Prior art keywords
- improved antitumoral
- antitumoral treatments
- treatments
- improved
- combinations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a combinaciones de PM02734 con otro fármaco anticancerígeno seleccionado de cisplatino, gemcitabina, paclitaxel, oxaliplatino, 5-fluorouracilo, trabectedina, rapamicina y sunitinib, y al uso de estas combinaciones en el tratamiento del cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08380078 | 2008-03-07 | ||
PCT/EP2009/052649 WO2009109649A1 (en) | 2008-03-07 | 2009-03-06 | Improved antitumoral treatments |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010009782A true MX2010009782A (es) | 2010-09-30 |
Family
ID=40627578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010009782A MX2010009782A (es) | 2008-03-07 | 2009-03-06 | Tratamientos antitumorales mejorados. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20110015135A1 (es) |
EP (1) | EP2262522A1 (es) |
JP (1) | JP2011513370A (es) |
KR (1) | KR20100126479A (es) |
CN (1) | CN101965192A (es) |
AU (1) | AU2009221120A1 (es) |
CA (1) | CA2717117A1 (es) |
IL (1) | IL208000A0 (es) |
MX (1) | MX2010009782A (es) |
RU (1) | RU2010140890A (es) |
WO (1) | WO2009109649A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10272068B2 (en) | 2012-01-17 | 2019-04-30 | Tyme, Inc. | Pharmaceutical compositions and methods |
US10646552B2 (en) | 2012-01-17 | 2020-05-12 | Tyme, Inc. | Pharmaceutical compositions and methods |
US20130183263A1 (en) | 2012-01-17 | 2013-07-18 | Steven Hoffman | Pharmaceutical compositions and methods |
US8481498B1 (en) | 2012-01-17 | 2013-07-09 | Steven Hoffman | Pharmaceutical compositions and methods |
WO2014010742A1 (ja) * | 2012-07-13 | 2014-01-16 | 学校法人神戸学院 | モノガラクトシルジアシルグリセロール又はその薬学的に許容し得る塩を有効成分として含む医薬組成物又は食品組成物 |
US10751313B2 (en) | 2013-10-22 | 2020-08-25 | Yamo Pharmaceuticals Llc | Compositions and methods for treating autism |
US9585841B2 (en) | 2013-10-22 | 2017-03-07 | Tyme, Inc. | Tyrosine derivatives and compositions comprising them |
US9326962B2 (en) | 2013-10-22 | 2016-05-03 | Steven Hoffman | Compositions and methods for treating intestinal hyperpermeability |
US9763903B2 (en) | 2013-10-22 | 2017-09-19 | Steven Hoffman | Compositions and methods for treating intestinal hyperpermeability |
US10813901B2 (en) | 2013-10-22 | 2020-10-27 | Yamo Pharmaceuticals Llc | Compositions and methods for treating autism |
JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
WO2020159171A2 (ko) * | 2019-02-01 | 2020-08-06 | (주)엠디바이오랩 | 스트렙토니그린 및 항암제를 포함하는 대장암 예방 또는 치료용 약학적 조성물 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
US4943533A (en) * | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
CA2082160C (en) * | 1991-03-06 | 2003-05-06 | Mary M. Bendig | Humanised and chimeric monoclonal antibodies |
AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
US6274551B1 (en) * | 1994-02-03 | 2001-08-14 | Pharmamar, S.A. | Cytotoxic and antiviral compound |
GB9302046D0 (en) * | 1993-02-03 | 1993-03-24 | Pharma Mar Sa | Antiumoral compound-v |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
ID19609A (id) * | 1996-07-13 | 1998-07-23 | Glaxo Group Ltd | Senyawa-senyawa heterosiklik |
US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
RS49779B (sr) * | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
US6200598B1 (en) * | 1998-06-18 | 2001-03-13 | Duke University | Temperature-sensitive liposomal formulation |
JP3687900B2 (ja) * | 1998-11-19 | 2005-08-24 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | チロシンキナーゼの不可逆的阻害剤であるn−[4−(3−クロロ−4−フルオロフェニルアミノ)−7−(3−モルホリン−4−イルプロポキシ)キナゾリン−6−イル]アクリルアミド |
US7311924B2 (en) * | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
UA74803C2 (uk) * | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
GB0002952D0 (en) * | 2000-02-09 | 2000-03-29 | Pharma Mar Sa | Process for producing kahalalide F compounds |
ATE314084T1 (de) * | 2000-10-31 | 2006-01-15 | Pharma Mar Sa | Kahalalid f formulierung |
US20050054555A1 (en) * | 2001-10-19 | 2005-03-10 | Jose Jimeno | Kahalalide compounds for use in cancer therapy |
EP1572726B1 (en) * | 2002-10-18 | 2010-12-08 | Pharma Mar, S.A.U. | 4-methylhexanoic kahalalide f compound |
GB0304367D0 (en) * | 2003-02-26 | 2003-04-02 | Pharma Mar Sau | Methods for treating psoriasis |
US7507708B2 (en) * | 2003-02-26 | 2009-03-24 | Pharma Mar, S.A.U. | Antitumoral compounds |
GB0321066D0 (en) * | 2003-09-09 | 2003-10-08 | Pharma Mar Sau | New antitumoral compounds |
EP1715971A4 (en) * | 2004-01-28 | 2010-10-13 | Cytimmune Sciences Inc | FUNCTIONALIZED COLLOIDAL METAL COMPOSITIONS AND METHODS |
GB0408958D0 (en) * | 2004-04-22 | 2004-05-26 | Pharma Mar Sa | Convergent synthesis for kahalalide compounds |
EP2029155B1 (en) * | 2006-02-28 | 2016-04-13 | Pharma Mar S.A. | Improved treatment of multiple myeloma |
MX2010004259A (es) * | 2007-10-19 | 2010-08-31 | Pharma Mar Sa | Tratamientos antitumorales mejorados. |
-
2009
- 2009-03-06 WO PCT/EP2009/052649 patent/WO2009109649A1/en active Application Filing
- 2009-03-06 CA CA2717117A patent/CA2717117A1/en not_active Abandoned
- 2009-03-06 CN CN2009801081376A patent/CN101965192A/zh active Pending
- 2009-03-06 MX MX2010009782A patent/MX2010009782A/es not_active Application Discontinuation
- 2009-03-06 US US12/920,433 patent/US20110015135A1/en not_active Abandoned
- 2009-03-06 EP EP09716581A patent/EP2262522A1/en not_active Withdrawn
- 2009-03-06 RU RU2010140890/15A patent/RU2010140890A/ru unknown
- 2009-03-06 JP JP2010549156A patent/JP2011513370A/ja active Pending
- 2009-03-06 AU AU2009221120A patent/AU2009221120A1/en not_active Abandoned
- 2009-03-06 KR KR1020107022265A patent/KR20100126479A/ko not_active Application Discontinuation
-
2010
- 2010-09-05 IL IL208000A patent/IL208000A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2009109649A1 (en) | 2009-09-11 |
AU2009221120A1 (en) | 2009-09-11 |
JP2011513370A (ja) | 2011-04-28 |
IL208000A0 (en) | 2010-12-30 |
EP2262522A1 (en) | 2010-12-22 |
RU2010140890A (ru) | 2012-04-20 |
CA2717117A1 (en) | 2009-09-11 |
KR20100126479A (ko) | 2010-12-01 |
US20110015135A1 (en) | 2011-01-20 |
CN101965192A (zh) | 2011-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010009782A (es) | Tratamientos antitumorales mejorados. | |
CY1118216T1 (el) | Μεθοδοι αγωγης καρκινου | |
PH12016502066A1 (en) | Methods of treating bladder cancer | |
MX2012003851A (es) | Tratamiento de cánceres resistentes antagonistas notch1, mediante el uso de antagonistas notch3. | |
MX2015008898A (es) | Metodos para el tratamiento de cancer pancreatico. | |
MX2013000779A (es) | Metodos para tratar cancer de mama utilizando 4-yodo-3-nitrobenzamida en combinacion con agentes antitumorales. | |
MX360404B (es) | Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr. | |
MX2016000131A (es) | Nanoparticulas polimericas de docetaxel para el tratamiento de cancer. | |
IN2012DN02018A (es) | ||
MX2010003299A (es) | Oligonucleotidos muy cortos (micromirs). | |
TN2013000227A1 (en) | Use of sigma ligands in bone cancer pain | |
MX2013006392A (es) | Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1. | |
PT2155188E (pt) | Métodos e composições para o tratamento de cancro recorrente | |
CL2007002640A1 (es) | Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer. | |
CL2007002642A1 (es) | Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer. | |
MA33810B1 (fr) | Compositions pour traiter les nausées et vomissements à médiation centrale | |
PH12018501339A1 (en) | Combination therapy | |
WO2009140675A3 (en) | Combination therapy with pm00104 and another antitumor agent | |
WO2009143454A3 (en) | Combination antitumor therapy | |
MX342947B (es) | Tratamiento de diabetes tipo 2. | |
MX2015003343A (es) | Tratamiento combinado con el farmaco de interferencia de netrina-1 y el farmaco quimioterapeutico. | |
MX2010008994A (es) | Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario. | |
MX2010000223A (es) | Compuestos de triazina novedosos para el tratamiento de cancer. | |
WO2010062143A3 (ko) | L1cam의 활성 또는 발현을 억제하는 물질 및 항암제를 포함하는 항암용 조성물 | |
MX2010009697A (es) | Tratamientos anticancerigenos mejorados. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |